• Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
TheraCryf
  • Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
Mobile close button Mobile toggle button

The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology

mel | 1 February 2021
Categories:

Post navigation

← Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
2021 Placing and Open Offer shareholder circular →
  • Privacy Policy
  • Data Protection Complaints Handling Process
  • Sitemap
Get in touch
LinkedIn

© 2026 TheraCryf. ICO Reg: ZB396415. Company Number: 09246681.